MET and cancer: A pharmacokinetic-pharmacodynamic (PK-PD) model conducted by Jones et al. found that savolitinib effectively inhibited the activity of phospho-MET, a protein associated with cancer, in a xenograft mouse model using human lung and gastric cancer cell lines [25].